Elucid

Elucid is a Boston-based medical technology company applying AI to cardiovascular diagnostics. Its PlaqueIQ-powered imaging analysis software is an FDA-cleared CT angiography tool that non-invasively quantifies and characterizes arterial plaque against a histologic ground truth, helping physicians assess heart attack and stroke risk. The software is commercially available in the US, UK, EU and South Korea.

  • Series C+
  • AI/ML
  • Healthtech
  • Medical Imaging
  • Medtech
  • Healthcare & Life Sciences

1

Round

1

Industry

5

Tags

Sep 2, 2026

Latest raise

Funding activity · 1 round

Raise timeline

  1. Sep 2, 2026

    $55M

    Series C+

    • Elevage Medical Technologies
    • IAG Capital Partners

    Article coming soon.

Pricing

Research Elucid — then scale the playbook

Public hubs orient you on the raise. Paid plans unlock live AI adoption signals across your market.

Enterprise

Custom pricing for unlimited scale. Let's talk.

Contact sales

Growth plan

For individuals and small teams getting started with AI buyer intelligence.

$149

/month

Get started

Features

  • Access to core AI adoption signals
  • 3–5 curated slices per week
  • 30–60 companies / week
  • AI Adoption Score
  • Deal-ready insights (why + pitch angle)
  • Basic filters (recency, slice, score)
  • CSV export
Most popular

Pro plan

For outbound teams and agencies that need more coverage and faster signal cadence.

$249

/month

Get started

Features

  • Everything in Growth, plus:
  • Full access to all slices
  • 60–120 companies / week
  • Higher-frequency signal updates
  • Priority / early signals (before Growth)
  • Advanced filters (industry, size, use case)
  • Deeper company insights
  • Faster export + bulk workflows

Act on this raise

See if Elucid is moving on AI

Funding is the starting point. VeilStrat shows whether capital is showing up as hiring, tools, and web activity you can sell into.

Start freeAll fundingVisit website
© 2026 VeilStrat. All rights reserved.All systems operational